alexa Immunogenicity and Efficacy of Coxsackievirus A16 Vaccine Candidate Formulations in a Mouse Model | OMICS International | Abstract

Journal of Molecular Immunology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article

Immunogenicity and Efficacy of Coxsackievirus A16 Vaccine Candidate Formulations in a Mouse Model

Jia Lu1, Linlin Zhang1, Taixue An1, Qunying Mao2, Pengfei Li1, Fukun Zhang1, Li Li1, Hui Zhou1, Jiling Wang1, Xiaoqi Chen1, Zejun Wang1*, Zhenglun Liang2and Shuo Shen1

1Department of Viral Vaccine Research, Wuhan Institute of Biological Product (WIBP) Ltd. Co., Wuhan 430207, PR China

2National Institutes for Food and Drug Control, Beijing 100050, PR China

*Corresponding Author:
Shuo Shen
Department of Viral Vaccine Research
Wuhan Institute of Biological Product (WIBP) Ltd. Co
Wuhan 430207, PR China
Tel: +86 27 88925340
Fax: +86 27 88842261
E-mail: wangzejun��sinopharm.com

Received Date: October 17, 2016; Accepted Date: January 09, 2017; Published Date: January 13, 2017

Citation: Lu J, Zhang L, An T, Mao Q, Li P, et al. (2017) Immunogenicity and Efficacy of Coxsackievirus A16 Vaccine Candidate Formulations in a Mouse Model. J Mol Immunol 1: 105.

Copyright: ©2017 Lu J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Besides enterovirus 71 (EV71), Coxsackie virus A16 (CVA16) is a major etiologic agent of hand, foot and mouth disease (HFMD), causing infections in millions of children under 5 years of age each year. The progress made in the development of inactivated EV71 vaccines encourages research aiming at developing a CVA16 vaccine for better prevention of HFMD and control of spreading of a rapidly evolvingvirus. The immunogenicity and efficacy of a CVA16 vaccine candidate were examined in a mouse model. Several vaccine formulations using different adjuvants and formalin-inactivated or non-inactivated full and empty virus particles were compared. It was observed that the CVA16-P4-L731 vaccine induced strong B and T cell immune responses in mice. The mouse antisera contained the highest titers of neutralizing antibodies reported so far and prevented infection of cells in vitro by prototype A and subgenotype B2b. Pups born to immunized mice were protected from disease and death following challenge by more than 10,000 LD50 of homologous and heterologous viruses. Taken together, the data suggest that the CVA17- P4-L731 is a promising vaccine candidate, either independently or as a valuable component for a combined [EV71+CVA16] bivalent vaccine.

Keywords

Leave Your Message 24x7
Top